Equity Research Pharmaceutical Preparations

Should You Buy NewAmsterdam Pharma Company N.V Stock in 2026?

By CirclFi Research Team · · 8/13 models active

According to the CirclFi Deep Alpha Valuation Engine, NewAmsterdam Pharma Company N.V (NAMSW) registers a weak Quality of Company score of 2.5/10. At the current price of $19.38, our 13-model framework evaluates whether the stock's discount is sufficient to compensate for high fundamental risks.

The short answer: 0 of 8 CirclFi valuation models project upside for NewAmsterdam Pharma Company N.V (NAMSW) at $19.38 — the model consensus leans bearish, with a Quality Score of 2.5/10 and Value-Trap risk of —/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 8 of 8 models suggest overvaluation — majority bearish
  • Quality Score: 2.5/10 — Very Weak — significant concerns
  • Value Trap Risk: —/100 — Not scored
  • Fair Value Range: $0.43 – $14.63 (3277% spread)

Bullish Models

0 / 8

Bearish Models

8 / 8

Quality Score

2.5 /10

Very Weak — significant concerns

Value Trap Risk

— /100
Not scored

Not scored

Model Consensus

8 /13
Active Models

Avg. confidence: 24%

Investment Thesis

The Bull Case

Currently, no active models project meaningful upside for NAMSW at $19.38. Bulls might argue that qualitative factors not captured by quantitative models could unlock value not reflected in current estimates.

The Bear Case

Target: $0.43 (-97.8%)

  • According to the CirclFi Quality of Company (QOC) framework, NewAmsterdam Pharma Company N.V's score of 2.5/10 signals fundamental weaknesses that could undermine the investment thesis.
  • According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model sees the stock as overvalued with a fair value of $0.43 (-97.8%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +73.3% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.
  • Industry headwind: drug pricing legislation represents a meaningful risk for NewAmsterdam Pharma Company N.V and its Pharmaceutical Preparations peers.

Peer Benchmarking

AZN AstraZeneca PLC
10.0
CPRX Catalyst Pharmaceuti
10.0
HRMY Harmony Biosciences
10.0
NVO Novo Nordisk A/S
10.0
SIGA SIGA Technologies In
10.0

See full Pharmaceutical Preparations rankings →

Valuation Divergence

Spread

3277%

Fair Value Range

$0.43 – $14.63

A 3277% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

FTNN

$14.63 (-24.5%)

Most Bearish

Regime Cross

$0.43 (-97.8%)

Key Risk Factors

Weak Fundamentals

QOC 2.5/10 signals below-average quality.

Model Disagreement

3277% spread signals high variance in projections.

Bearish Consensus

8/8 models suggest overvaluation.

Macro/Sector Risk

Pharmaceutical Preparations headwinds could affect earnings trajectory.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View NAMSW Data Page →

The Bottom Line

Our valuation engine sends a clear cautionary signal on NewAmsterdam Pharma Company N.V at $19.38. 8/8 models flag overvaluation, composite fair value sits at $5.97 (-69.2%), and the risk-reward profile appears unfavorable. Quality at 2.5/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. NewAmsterdam Pharma Company N.V's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy NAMSW stock right now?

Based on CirclFi's multi-model analysis, 0 of 8 models see upside for NAMSW at $19.38. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in NewAmsterdam Pharma Company N.V?

Key risks include: a below-average Quality Score of 2.5/10, indicating fundamental weakness; wide model disagreement (3277% spread), signaling high uncertainty; general market and sector-specific risks affecting Pharmaceutical Preparations companies. Always diversify and consult a financial advisor.

How does NAMSW compare to its competitors?

Among Pharmaceutical Preparations peers, NAMSW holds a Quality Score of 2.5/10. Comparable companies include AZN (QOC 10.0), CPRX (QOC 10.0), HRMY (QOC 10.0). The relative ranking helps investors identify whether NAMSW offers better fundamental quality than alternatives in the same sector.

Is NAMSW a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. NAMSW's Quality Score of 2.5/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.

What price should I buy NAMSW at?

CirclFi does not provide target buy prices or price alerts. However, our 8 active models produce fair value estimates ranging from $0.43 to $14.63. At $19.38, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for NAMSW.

View NAMSW Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →